Tag - PASG

Feature

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

Passage Bio (NASDAQ:PASG) is focused on developing transformative, differentiated therapies for rare, life-threatening monogenic CNS disorders, with the goal of mitigating development risk. “We believe that our rigorous...

June 30, 2020

Developments

Passage Bio gets rare pediatric disease designation for gangliosidosis

Passage Bio’s (NASDAQ:PASG) PGBM01 received FDA rare pediatric disease designation for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene impair...

May 21, 2020

Tag - PASG

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

Passage Bio gets rare pediatric disease designation for gangliosidosis

General

More